🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

♀️ on oral contraceptive (OC) has a provoked proximal🦵DVT due to cast immobilization. Should we discontinue OC🩸after cessation of anticoagulant therapy? New evidence suggests a 2.5 ⬆️ risk of recurrent VTE while on OC compared to non-users. authors.elsevier.com/a/1jTap5TuFxIt… JTH

MEGA case-control study also confirms that OC use is safe during anticoagulant therapy for VTE but risk of recurrent events ⬆️ following anticoagulation cessation (provoked or unprovoked). doi.org/10.1016/j.jtha… ISTH

As highlighted by NEJM this extremely prothrombotic entity, MGTS (Monoclonal gammopathy of thrombotic significance) may respond to myeloma therapy, as highlighted by this report Yazan Abou-Ismail, MD - د. يزن أبواسماعيل Krishna Gundabolu MBBS; MS Kristi J Smock, MD Professor Beverley Hunt OBE (also on BlueSky) Sigurdur Kristinsson Sæmundur Rögnvaldsson, MD, PhD

One dose of LMWH or UFH in the OR may be associated with a non-significant improved DFS at 3 years, shown in the new post-hoc analysis of PERI-OP 01 trial authors.elsevier.com/c/1jgDr_17tKVJ… Marc Carrier Ottawa Methods Centre

Dual direct oral anticoagulant therapy in challenging thrombosis: a case series - Research and Practice in Thrombosis and Haemostasis rpthjournal.org/article/S2475-…

Important new Periop Guidelines for #antiplatelet, #DOACs, and #warfarin 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Su… pubmed.ncbi.nlm.nih.gov/39316661/ @NATFthrombosis Anticoagulation Forum PERT Consortium Thrombosis Canada

Happy to share our experience The Ottawa Hospital🏥 with a weight-based 4F-PCC 25-50 IU/kg protocol💉for FXaI-associated🩸or before urgent surgery‼️Thrombosis Research Abdul Al-Mujalli Yan Xu Jerrold Levy, MD Sam Schulman Deborah Siegal Marc Carrier Lana Castellucci sciencedirect.com/science/articl…

bmcnephrol.biomedcentral.com/articles/10.11…

Do you struggle with whether to use anticoagulation for tumor thrombus? Hui et al. showed that patients with tumor thrombus have high risks of VTE, bleeding and mortality, and unfortunately the role of anticoagulation remains unclear. Tzu-Fei Wang Marc Carrier Read more at

📢Join our upcoming Research Recap on “Heavy menstrual bleeding on direct factor Xa inhibitors - The MEDEA Randomized Clinical Trial.” The authors of this exciting RPTH article will give you a recap of the study & answer live questions from the audience! Register here:

nejm.org/doi/full/10.10…

The new thrombophilia, MGTS just got more interesting, and complicated! Here is a new paper in NEJM from our group on the challenges of recognizing this disorder: nejm.org/doi/full/10.10… Couple of other recent papers on MGTS: nejm.org/doi/abs/10.105… ashpublications.org/blood/article/…

Dr. Ang Li, MD, MS reported external validation of the EHR-CAT score (adaptions of the Khorana risk score) in 187 health care system (over 400,000 patients). Let’s implement this in EPIC to stratify patients according to their underlying risk of VTE! #ASH24

Interesting results with abelacimab in patients with AF NEJM 👇 Can uncoupling hemostasis and thrombosis by blocking FXI also help address unmet need in cancer-associated thrombosis? Can't wait for the results of the ASTER and MAGNOLIA trials! nejm.org/doi/full/10.10… @Anthos_Tx

One of the best thrombosis programs in the world Marc Carrier Deborah Siegal Tzu-Fei Wang Université d'Ottawa | University of Ottawa

nejm.org/doi/full/10.10…

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! thelancet.com/journals/lance… Francis Couturaud

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…